Product Description
Mechanisms of Action: TXA2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Institut de Recherches Internationales Servier
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Stroke
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2007-000176-17 |
2007-000176-17 | P2 |
Completed |
Stroke |
2009-04-20 |
2022-03-12 |
Treatments |
|
2005-003700-10 |
PERFORM | P3 |
Completed |
Stroke |
2010-01-27 |
2022-03-12 |
Treatments |